Last $15.36 USD
Change Today -0.36 / -2.29%
Volume 2.5M
SGMO On Other Exchanges
Symbol
Exchange
SGMO is not on other exchanges.
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

sangamo biosciences inc (SGMO) Snapshot

Open
$15.68
Previous Close
$15.72
Day High
$16.05
Day Low
$14.92
52 Week High
03/19/14 - $24.69
52 Week Low
10/13/14 - $9.39
Market Cap
1.1B
Average Volume 10 Days
1.6M
EPS TTM
$-0.46
Shares Outstanding
68.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SANGAMO BIOSCIENCES INC (SGMO)

sangamo biosciences inc (SGMO) Related Businessweek News

No Related Businessweek News Found

sangamo biosciences inc (SGMO) Details

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins could be used to turn genes on or off. The company’s principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops CERE-110 that is in Phase II clinical trial for the treatment of Alzheimer’s disease. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, huntington’s disease, and hemoglobinopathies; and proprietary programs in the areas of lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including various immunodeficiencies, as well as central nervous system disorders and cancer immunotherapy. The company has collaboration and license agreements with Shire International GmbH and Biogen Idec Inc.; and strategic partnerships with Sigma-Aldrich Corporation, Dow AgroSciences, LLC, Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.

85 Employees
Last Reported Date: 02/24/14
Founded in 1995

sangamo biosciences inc (SGMO) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $640.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $400.0K
Chief Medical Officer and Vice President of T...
Total Annual Compensation: $437.5K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $385.0K
Executive Vice President of Research and Deve...
Total Annual Compensation: $453.5K
Compensation as of Fiscal Year 2013.

sangamo biosciences inc (SGMO) Key Developments

Sangamo Biosciences Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 08:00 AM

Sangamo Biosciences Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 08:00 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Edward O. Lanphier, Founder, Chief Executive Officer, President, Director and Member of Clinical Review Committee.

Sangamo Biosciences Inc. Announces Unaudited Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2014; Reiterates Earnings Guidance for the Year of 2014

Sangamo Biosciences Inc. announced unaudited consolidated financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $12.417 million against $5.707 million a year ago. Loss from operations was $7.654 million against $6.159 million a year ago. Net loss was $7.545 million or $0.11 per diluted share against $6.145 million or $0.11 per diluted share a year ago. Net cash used in operating activities was $5.8 million. For the nine months, the company reported total revenues of $30.918 million against $17.264 million a year ago. Loss from operations was $22.312 million against $18.532 million a year ago. Net loss was $22.098 million or $0.33 per diluted share against $18.480 million or $0.34 per diluted share a year ago. Net cash used in operating activities was $3 million. The company reiterated its earlier guidance. The company expects that revenues will be in the range of $45 million to $50 million in 2014, inclusive of research funding and certain milestone payments from Shire and Biogen.

Sangamo Biosciences Inc. to Report Q3, 2014 Results on Oct 22, 2014

Sangamo Biosciences Inc. announced that they will report Q3, 2014 results at 5:00 PM, US Eastern Standard Time on Oct 22, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGMO:US $15.36 USD -0.36

SGMO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bluebird Bio Inc $92.00 USD +1.02
Fibrocell Science Inc $2.68 USD +0.10
View Industry Companies
 

Industry Analysis

SGMO

Industry Average

Valuation SGMO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.7x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANGAMO BIOSCIENCES INC, please visit www.sangamo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.